The week in pharma: action, reaction and insight – week to January 12, 2024

14 January 2024

By Barbara Obstoj-Cardwell. Editor

M&A activity continued to feature in last week’s news, with US healthcare giant Johnson & Johnson announcing a $2 billion acquisition of antibody-conjugate (ADC) developer Ambrx Biopharma and its candidate ARX517. Also, pharma giant Merck & Co revealed a $680 million bid for fellow USA-based Harpoon Therapeutics to expand its oncology pipeline with HPN328. In other news, US pharma major AbbVie announced the launch in Europe of its new Parkinson’s disease treatment Produodopa. USA-based Xeris Biopharma entered into a technology licensing deal with biotech giant Amgen related to the development of Tepezza.

J&J to acquire ADC drug developer Ambrx for $2 billion

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK